Abstract

Purpose. Speed of bloodstream infection diagnosis is vital to reduce morbidity and mortality. Whole genome sequencing (WGS) performed directly from liquid blood culture could provide single-assay species and antibiotic susceptibility prediction; however, high inhibitor and human cell/DNA concentrations limit pathogen recovery. We develop a method for the preparation of bacterial DNA for WGS-based diagnostics direct from liquid blood culture.

Methodology. We evaluate three commercial DNA extraction kits: Biostic Bacteraemia, Amplex Hyplex and MolYsis Plus. Differential centrifugation, filtration, selective lysis and solid-phase reversible immobilization bead clean-up are tested to improve human cells/DNA and inhibitor removal. Using WGS (Illumina/MinION), we assess human DNA removal, pathogen recovery, and predict species and antibiotic susceptibility in positive blood cultures of 44 Gram-negative and 54 Staphylococcus species.

Results/Key findings. Biostic kit extractions yield the greatest mean DNA concentration, 94–301 ng µl⁻¹, versus 0–2.5 ng µl⁻¹ using Amplex and MolYsis kits. However, we note higher levels of inhibition (260/280 ratio 0.9–2.1) and human DNA (0.0–4.4 × 10⁶ copies) in Biostic extracts. Differential centrifugation (2000 g, 1 min) prior to Biostic extraction reduces human DNA by 63–89 % with selective lysis minimizing by a further 62 %. Post-extraction bead clean-up lowers inhibition. Overall, 67 % of sequenced samples (Illumina MiSeq) contain <1.0 % human DNA, with >93 % concordance between WGS-based species and susceptibility predictions and clinical diagnosis. If >60 % of sequencing reads are human (7/98 samples) susceptibility prediction becomes compromised. Novel MinION-based WGS (n=9) currently gives rapid species identification but not susceptibility prediction.

Conclusion. Our method for DNA preparation allows WGS-based diagnosis direct from blood culture bottles, providing species and antibiotic susceptibility prediction in a single assay.
INTRODUCTION

Bacterial bloodstream infections (BSIs) are a major cause of morbidity and mortality [1, 2]. In England, Public Health England (PHE) report the 2015/16 30-day mortality rate of BSI of major pathogens (Escherichia coli, methicillin-sensitive Staphylococcus aureus and methicillin-resistant S. aureus) as 14.7, 19.7 and 28.1% respectively, with E. coli mortality highest overall (5738 deaths) [3]. Early appropriate antimicrobial therapy is crucial to reduction of BSI-related mortality and morbidity, length of stay and healthcare costs [4–10]. However, review of empirical BSI therapy follows phenotypic identification and antimicrobial susceptibility testing (AST) of bacterial species, a time-consuming process that delays targeted therapy. Given empirical therapy may be inappropriate in up to 40% of cases [5], and the continued growth in the prevalence of antimicrobial resistant bacteria [11], an earlier informed and targeted therapy for BSI is becoming increasingly important [4–10].

Methods for rapid, automated, organism identification and phenotypic testing, such as matrix-assisted laser desorption/ionization mass spectrometry (MALDI-TOF MS; e.g. Bruker, USA) and automated microbroth dilution (e.g. BD Phoenix; BD, USA) respectively, reduce turnaround time and demonstrate the positive benefits associated with earlier appropriate therapy [12]. Despite these advances, reliance on pure microbial culture continues. Depending on the micro-organism, conventional laboratory workflows can therefore vary from 24 h to several weeks to complete [5–13].

Species identification and AST methods directly from primary blood culture have the potential to reduce turnaround times, and show benefits in clinical care [4–10]. For example, MALDI-TOF methods have been adapted for this purpose, with varying degrees of accuracy [14, 15]. However, MALDI-TOF cannot provide full drug susceptibility information from primary culture [4, 6–8]. Microarray and PCR-based molecular tests target panels of species-specific and drug-resistance markers in primary culture [8, 9]. Although molecular methods report rapid and accurate diagnosis [8, 9], panel sizes are limited and none encompass the full diversity of BSI-causing bacteria and drug-resistance markers (for examples see [16–21]). Sequence divergence in the primer region may affect sensitivity of these assays whereas the impact of DNA contamination, from both human and other bacterial cells, affects the specificity. Thus, molecular approaches continue to present a challenge [22, 23].

Whole genome sequencing (WGS) offers a solution to the limitations of PCR-based methods, providing species identification that is un-restricted by a target panel, with the advantages of antimicrobial susceptibility prediction, lineage and information regarding relatedness to other isolates using the same data. Retrospective investigations for pure cultures of E. coli, Klebsiella pneumoniae and S. aureus demonstrate that WGS diagnostic accuracy is comparable to routine phenotyping methods [24, 25]. WGS directly from primary blood culture could reduce turnaround times to a clinically applicable time-frame. However, this is more challenging, reliant on the removal of a diverse range of inhibitors present in the liquid media [7, 26], and depletion of human cells and/or DNA to allow recovery of sufficient good-quality pathogen DNA. Initial bacterial density in BSI falls between 1–100 c.f.u. ml⁻¹ [27] and even post-primary culture recovery of bacterial DNA for successful WGS is complicated by the presence of large amounts of human DNA.

We report a method to deplete human cells/DNA and isolate bacterial DNA of sufficient quality and quantity for WGS direct from primary liquid blood culture. We demonstrate the ability of the method to provide species identification using short-read Illumina sequencing and the emerging long-read Nanopore MinION system, as well as antimicrobial-resistance prediction using Illumina sequencing data.

METHODS

Sample collection and processing

Positive blood culture specimens identified as containing either Gram-negative organisms or Staphylococcus sp. by routine clinical Gram-stain were retrieved from the Oxford University Hospitals National Health Service (UK) (NHS) Foundation Trust microbiology laboratory. Blood culture bottles collected included the BD BACTEC Aerobic Plus, Peds Plus, and Lytic Anaerobic (BD, USA). The former two contain resin, and the latter lytic agents for the release of intracellular pathogens. Positive samples from the previous 24 h were retrieved by 10am each working day. Samples were stored at 37 °C between positivity and collection, 5 ml of culture was immediately removed and retained for processing.

DNA extraction and pre-steps

Three DNA extraction and purification kits were tested: MoYsis Plus kit (Molzym, Germany), BiOstic Bacteraemia kit (MoBio, Qiagen, USA) and Amplex Hyplex Quickprep (Amplex Biosystems, Germany) following the manufacturers’ protocol. Chosen kits were readily available in the UK and designed to remove inhibitors to molecular testing. DNA extracted using BiOstic Bacteraemia kit was analysed with and without subsequent DNA purification using AMPure XP solid-phase reversible immobilization (SPRI) beads following the manufacturer’s protocol (Beckman Coulter, UK). BiOstic kit extractions were also performed with pre-treatment steps for the depletion of human DNA. These steps were differential centrifugation of primary culture, selective lysis of the primary culture pellet, filtration of primary culture, and a combination of the methods (fully detailed in Fig. S1, available in the online version of this article). DNA was quantified and qualified using the NanoDrop 1000 or Qubit 2.0 fluorometer (double-stranded DNA high sensitivity/broad range kits as required; Thermo Fisher Scientific, USA).
**Quantitative PCR (qPCR)**

Quantitative PCR using the probes and primers described in Table S1 was used to quantify *S. aureus*, *E. coli* or 16S rRNA, as well as human GAPDH or β-actin DNA (Fig. S1). *S. aureus*, *E. coli* and human GAPDH primers and probes were used at a final concentration of 0.32 µM, 16S primers and a probe were used at 0.1 µM, human β-actin primers were used at 0.5 µM and the probe at 0.2 µM. All reactions used 1X Brilliant Multiplex qPCR Master Mix (Agilent, USA) with 2 µl DNA and sufficient molecular grade water to bring the reaction volume to 25 µl. Amplification was performed using the MxPro 3005P (Agilent, USA) under the following conditions: 95°C for 10 min, 40 cycles of 95°C for 15 s and 60°C for 1 min. Extraction showing evidence of inhibition were re-amplified using 2 µl of 1:10 and 1:100-fold diluted DNA, and following SPRI bead clean-up.

**Illumina MiSeq whole genome sequencing**

The finalized protocol (Fig. S1) was used to prepare samples for WGS (finalized protocol, Fig. S1). Bacteria and other debris were pelleted via differential centrifugation of primary culture (1000 g, 1 min). The pellet was retained, re-suspended in 1 ml molecular grade water and incubated at room temperature for 5 min to selectively lyse human cells. The suspension was re-pelleted (17 000 g, 3 min) and the pellet taken forwards to DNA extraction, or re-suspended in 1 ml nutrient broth with 10% glycerol and stored at -20°C until extraction. DNA extraction was performed using the BiOstic kit followed by SPRI bead clean-up. Sequencing libraries were prepared using the Nextera XT kit (Illumina, USA) following the manufacturer’s protocol with manual library normalization. Sequencing was performed using MiSeq v2 2×150 base pair (bp) paired-end read cartridges and MiSeq v3 2×75 or 2×300 bp paired-end read cartridges.

**MinION whole genome sequencing**

As DNA input requirements for MinION sequencing are higher than for MiSeq, 10 ml blood culture was processed per sample. *S. aureus* and *E. coli* DNA extracts (finalized protocol, Fig. S1) were prepared for MinION sequencing using the Rapid Sequencing Kit (SQK-RAD002; RSE_9018_v2_redD_21Nov2016) following the manufacturer’s protocol. Sequencing was performed using R9.4 flow cells for 48 h and sequencing reads live basecalled in MinKNOW version 1.2–1.3 (ONT, UK).

**Sequence analysis**

MiSeq sequencing data was processed via an in-house pipeline. Reads were classified with the metagenomic classifier, Kraken (database built from bacterial, viral and human genomes present in National Center for Biotechnology Information refseq on 14 January 2015; v0.10.6-unreleased) [28], and human reads removed. Remaining reads were mapped (stammy v1.0.23) to a reference genome chosen according to the top species hits from Kraken (for *S. aureus* GenBank BX571856.1 and for *E. coli* GenBank AE014075.1). For *Staphylococcus* sp. specimens, the species was also predicted via the publically available Mykrobe Predictor [29]. Mykrobe also predicts antibiotic susceptibility for *S. aureus* (Mykrobe v0.3.6–0-g9d196c7), while antibiotic susceptibility for *E. coli* and Klebsiella sp. was predicted using resistType (https://github.com/hangphan/resistType), an in-house algorithm using a previously published catalogue of resistance conferring mutations/genes [25]. We determined sequencing quality through assessment of overall genome coverage and depth of coverage from both MinYkrobe and mapping analysis, as well as the total number of reads available.

Predictions of genotype (species and antimicrobial resistance) from Mykrobe for *Staphylococcus* sp.; species from Kraken and antimicrobial resistance from resistType for *E. coli* and Klebsiella sp.) were compared to anonymized clinical diagnosis generated using pure culture isolates (species from Bruker microflex MALDI-TOF MS (Bruker, USA), antimicrobial resistance from BD Phoenix microbroth dilution (BD, USA)). In all cases the clinical diagnosis was taken as the gold standard comparator method. The sensitivity (clinical positives/clinical positives+WGS false negatives) and specificity (clinical negatives/clinical negatives+WGS false positives) of WGS-based diagnosis was calculated. When analysing concordance between Kraken data and clinical species identification, we disregarded organisms with <1% of available reads assigned to them.

For MinION-generated reads fastq and timing data was extracted in real time and iteratively updated using fast5-Watcher.py (https://github.com/nick297/fast5_scripts; commit vb88e14a). We conducted metagenomic classification using Kraken with no filtering threshold. We predicted antibiotic susceptibility via Mykrobe for samples identified as *S. aureus* (v0.4.3–0-gd6c8714), and for *E. coli* and Klebsiella sp.-resistance predictors were identified by BLAST against the published mutation/gene catalogue [25]. Mykrobe provided data quality parameters including depth of species and resistance mechanisms for *S. aureus*. The number of bases recovered, read number and length statistics, and accuracy, were calculated for all runs using nanoStats.py (https://github.com/nick297/fast5_scripts; commit vb88e14a).

**RESULTS**

**DNA extraction optimization**

Measurement of DNA yields from 23 positive blood cultures (*E. coli*, n=11, *S. aureus*, n=12) from 17 individuals (aerobic and anaerobic blood culture processed from 6/17 individuals) followed extraction using the three commercially available kits. According to manufacturers, all kits remove inhibitors and deplete human cells.

Initial yields from six *E. coli* and six *S. aureus* positive samples demonstrated that the BioOstic kit provides the most DNA (Qubit fluorometer), with mean values up to 430x greater than MolYsis or AmpLex (Table 1). All BioOstic extracts contained detectable DNA, while in 2/6 MolYsis
Table 1. DNA yield for 12 samples extracted using Amplyx Hyplex Quickprep, BiOstic Bacteraemia, and MolYsis Plus kits

Mean, sd and inter-quartile range (IQR) values were measured using the Qubit double-stranded DNA high sensitivity or broad range quantification kit shown (kits used as required). 0=DNA below detection limits of high sensitivity quantification kit.

| Measurement          | Sample numbers | Extraction kit     | E. coli | S. aureus |
|----------------------|----------------|-------------------|---------|-----------|
| Qubit (ng µl⁻¹)      | 6x E. coli, 6x S. aureus | Amplex         | 0.7     | 0.0       |
|                      |                | BiOstic          | 300.5   | 90.4      |
|                      |                | MolYsis          | 2.5     | 0.2       |

Table 2. qPCR copy number data samples extracted using MolYsis Plus and BiOstic Bacteraemia kits; human DNA measured using GAPDH qPCR target (Table S1).

Mean, sd and inter-quartile range (IQR) values are shown. 0=DNA undetectable. N/A=data not available as only two samples tested.

and 5/6 Amplyx no S. aureus DNA was detected. On this basis, Amplyx was disregarded as a suitable method to extract DNA from blood cultures for WGS purposes.

qPCR assessment of the 12 initial extracts was performed using S. aureus, E. coli and human GAPDH targets (Table S1). MolYsis extracts yielded 10⁵–10⁶ copies [inter-quartile range (IQR)] for E. coli and S. aureus; alongside 0–10² human copies (IQR; Table 2). The six BiOstic extracts initially failed to amplify, but amplification of diluted input DNA with and without SPRI bead clean-up (n=4) yielded 10³–10⁶ copies of S. aureus and E. coli; alongside 0–10⁶ human copies (IQR; Table 2). This suggests amplification may be inhibited by contaminants carried over during the extraction process or from excessive DNA.

Additional contamination analysis was performed using the NanoDrop on fresh MolYsis extractions (S. aureus n=6; E. coli n=5; Table S2), and BiOstic extractions with and without SPRI clean-up (S. aureus n=3; E. coli n=3; Table S2). All initial extracts had low 260/230 ratios (ranges: S. aureus 0.9–1.5; E. coli 0.7–2.2) with low 260/280 ratios also seen in BiOstic extracts (IQR S. aureus 0.2–2.2, E. coli 0.9–2.1; Table S2); indicating carry-over of contaminants from the extraction process. DNA yields in BiOstic extracts were 30x higher than MolYsis, allowing SPRI clean-up to improve DNA purity. Clean-up reduced mean DNA yield to 39.3 ng µl⁻¹ for E. coli and 11.5 ng µl⁻¹ for S. aureus, but increased purity, indicated by higher 260/280 (IQR S. aureus 1.4–2.2, E. coli 1.9–2.2; Table S2) and 260/230 ratios (IQR S. aureus 1.9–2.7, E. coli 2.2–2.3; Table S2).

Overall, yields in E. coli samples exceeded S. aureus from both extraction kits, possibly due to incomplete lysis of S. aureus without a specific lysis enzyme (e.g. lysostaphin). The MolYsis kit was more successful at human cell/DNA depletion, shown by the lower ratio of human to bacterial DNA as compared to BiOstic (Table 2). However, the higher bacterial DNA concentrations and the success of SPRI clean-up of BiOstic extractions indicates the validity of this method for further testing to enhance human cell depletion.

Depletion of human cells/DNA optimization

All human cell/DNA depletion experiments were assessed using qPCR (Fig. S1, Tables S1 and S3). Differential centrifugation was performed for two fresh samples to determine what speed and time effectively depleted human copy number (Fig. S1; pre-step a) from initial values of 248 in sample 1 and 56 in sample 2. In sample 1, 2000 g centrifugation, for both 30 s and 1 min demonstrated the greatest reduction in
human copy number (63–77%; Table S3) whereas in sample 2 centrifugation at 1000 g for 30 s and 1 min reduced copy number by >90%. Variation in relative bacterial load was minimal; other than in 3000 g for 1 min centrifugation which depleted bacterial cells (Table S3).

Inclusion of an additional distilled water wash (Fig. S1 pre-step b) resulted in an extra 62% (mean; range 37–80%; n=7) depletion of human cells (data not shown).

Fresh S. aureus positive specimens were collected to assess the efficacy of a filtration step (Fig. S2; pre-step c). However, filtration resulted in variability in S. aureus DNA yield (IQR 6.7×10^4–1.0×10^6 versus 2.9×10^6–4.0×10^6; n=6) (qPCR; Table S1). Therefore, the filtration method was not taken further in this study.

Although 1000 g centrifugation resulted in the largest single reduction in human copy number seen across both samples, centrifugation at 2000 g reduced human DNA more effectively where burden was higher and was consequently incorporated into the final protocol alongside a distilled water wash (Table S3 and finalized protocol in Fig. S1).

Illumina MiSeq whole genome sequencing

MiSeq-based WGS on newly collected positive blood culture samples (Staphylococcus sp. 54 specimens, 51 individuals; Gram-negative bacteria 44 specimens, 42 individuals) measured the effectiveness of the final extraction process (Fig. S1; finalized protocol). Read numbers ranged from 1.5 to 5.2 million per sample (v2 cartridges: 1.5–3.73 million; v3 cartridges: 3.1–5.2 million). All repeat specimens from the same individual were identical in terms of species and drug susceptibility prediction.

Mykrobe [29] identified S. aureus with 100% sensitivity and 98% specificity in comparison to routine clinical identification [S. aureus identified by WGS in 14/14 routine clinical S. aureus positives+1 S. aureus identified by WGS only (‘false-positive’); Table 3]. Mykrobe achieved >99% reference genome coverage across all 14 S. aureus samples, with 13–152x depth; conversely the single additional S. aureus found had 24% reference genome coverage and 1x depth. This may represent a false-positive call by Mykrobe, or the presence of S. aureus at a low concentration. Across all 54 samples, Kraken [28] analysis assigned 0.01–95% (mean 24.5%, IQR 2.3–39.5%) of sequencing reads to human DNA (Fig. 1).

E. coli and Klebsiella sp. identification was 100 and 90% sensitive (E. coli identified by WGS in all 27 clinical positives; Klebsiella sp. identified by WGS in 8/9 clinical positives), and 100 and 97% specific respectively (0 additional E. coli specimens detected by WGS; 1 additional Klebsiella sp. specimen detected by WGS; Tables 3 and S4). Overall, Kraken assigned the same organism as routine clinical diagnosis in 93% (41/44) of specimens (Table S4). Three non-E. coli and non-Klebsiella sp. specimens were discrepant (MALDI-TOF Aeromonas sp., Acinetobacter iwoffii, and Vibacillus sp.; Kraken Enterobacter aerogenes, Acinetobacter baumannii, and unclassifiable). Polymicrobial infections were identified by clinical diagnosis in 12/44 cases (including two non-E. coli and non-Klebsiella sp. specimens); Kraken classified all species in 2/12 of these cases, while in 3/12 cases the un-identified organism(s) were found in an additional, un-sequenced, blood culture bottle (Table S4). For the remaining 7/12 cases, the co-infecting organisms were found at <0.5% of the total read number (3/7), or were undetectable by Kraken (4/7). Kraken identified additional organisms, not seen in clinical diagnosis, in 4/44 of cases (although at 1–2% of the total read number). The percentage of human DNA reads across all samples ranged from 0–15.7% (mean 1.2%, IQR 0.04–1.1%; Fig. 1).

Mykrobe provided drug susceptibility predictions across 12 antibiotics (Fig. 2) for 14 S. aureus samples [29]. Concordance was 95% (160/168) between Mykrobe prediction and phenotype. Of the discordant predictions, 88% (7/8) were in a single specimen; 4/7 of these discordant predictions

| Species identified                        | No. identified by MALDI-TOF | No. identified by WGS |
|------------------------------------------|----------------------------|-----------------------|
| Gram-positive blood cultures (n=54)      |                            |                       |
| Coagulase negative Staphylococci         | 37                         | 39                    |
| Staphylococcus aureus                    | 14                         | 15                    |
| Other                                    | 3                          | 0                     |
| Gram-negative blood cultures (n=44)      |                            |                       |
| Escherichia coli                         | 20                         | 24                    |
| Klebsiella pneumoniae                    | 4                          | 5                     |
| Klebsiella oxytoca                       | 1                          | 0                     |
| Klebsiella pneumoniae+Klebsiella oxytoca | 0                          | 1                     |
| Escherichia coli+Klebsiella sp.          | 3                          | 1                     |
| Escherichia coli+other (non-Klebsiella sp.) | 5                        | 2                     |
| Klebsiella sp.+other (non-Escherichia colii) | 2                      | 2                     |
| Other (non-Escherichia coli and non-Klebsiella sp.) | 9                      | 9                     |

Table 3. Summary of target species (Staphylococci sp., E. coli and Klebsiella sp.) identified by clinical diagnosis (MALDI-TOF) and WGS; full species breakdown provided in Table S4.
were low-frequency within-sample alleles (labelled ‘r’ by Mykrobe, Fig. 2). Amongst the 14 *S. aureus* isolates, depth of coverage was lowest, and human DNA contamination highest in the two specimens with discordant drug susceptibility predictions; 13–27× depth and 62–87 % human DNA content in comparison with 57–152× depth and 27–51 % human DNA content in concordant specimens.

Fig. 1. Assignment of reads by Kraken metagenomics analysis. (a) Gram-positive blood cultures (n=54). Reads are categorized as follows: *S. aureus*, other staphylococci (identification to genus level only, or non-*S. aureus*), other bacteria, human and other organisms (e.g. viruses). (b) Gram-negative blood cultures (n=44). Reads are categorized as follows: *E. coli*, *K. pneumoniae*, *K. oxytoca*, other Gram-negative bacteria, Gram-positive bacteria, human and other organisms (e.g. viruses).
Drug susceptibility predictions for clinically monomicrobial E. coli or Klebsiella sp. BSI (25 isolates) showed 97% (169/175) concordance using resistType. 2/6 discordant predictions were for specimens with intermediate MIC by standard laboratory methods (ciprofloxacin MIC 1 mg ml$^{-1}$; ceftazidime MIC 2 mg ml$^{-1}$; WGS sensitive for both). 3/6 discordant predictions were for co-amoxiclav (genotype S and phenotype R). No relevant genetic-resistance mechanisms were seen for both the co-amoxiclav and intermediate susceptibility discordants (using the catalogue described by Stoesser et al. [25]). The remaining discordant prediction (amoxicillin in a K. oxytoca isolate) was due to BD Phoenix.
algorithms automatically assigning a resistant phenotype with amoxicillin MIC elevated but below breakpoint (4 mg ml\(^{-1}\); 8 mg ml\(^{-1}\) breakpoint). No genetic resistance was reported by resist\(\text{T}\)ype.

**Rapid sequencing with MinION**

Rapid sequencing on nine blood culture positive samples (E. coli or S. aureus) using Nanopore MinION demonstrated three sequencing run failures, with 6–29 reads obtained, and six successful runs, >4000 reads (Table 4). In successful runs median 69.3\(\times\)10\(^6\) (IQR 11.7\(\times\)10\(^6\)–3.0\(\times\)10\(^7\)) bases were recovered with 88.4–89.7 % read accuracy.

In successful sequencing runs over 85 % of the proportion of reads were the infecting organism (Fig. 3). Real-time analysis allowed identification of infecting species within 10 min of sequencing commencing (Fig. S2), even where yield was variable. Approximately 80 % of total yield was obtained in the first 11 h of sequencing.

Depth of coverage was 4–33x for S. aureus and 12–210x for E. coli (Table 4). Drug susceptibility prediction was 97 % concordant in S. aureus (samples 3, 4, 9 in Table 4; data not shown) with one specimen fully susceptible, one penicillin resistant, and one penicillin and fusidic acid resistant. Mykrobe predicted one sample, phenotypically susceptible to trimethoprim-sulfamethoxazole, to be trimethoprim resistant. Susceptibility predictions for E. coli were 86 % concordant (samples 1, 2, 5 in Table 4; data not shown). One isolate was fully sensitive and one concordant for amoxicillin and co-amoxiclav resistance (TEM-30 identified). In the final sample, SHV was detected, leading to a concordant prediction of amoxicillin resistance. However, the SHV variant could not be differentiated, preventing genotypic prediction for ceftriaxone, ceftazidime and co-amoxiclav.

**DISCUSSION**

We demonstrate a human cell/DNA depletion and bacterial extraction method to allow WGS directly from aerobic and anaerobic BACTEC blood culture bottles. The method includes differential centrifugation to remove intact human cells, and a distilled water wash to lyse remaining human cells. Removal of free human DNA occurs following pelleting of bacterial cells. Following these steps, we extract bacterial DNA with a commercial kit (BiOstic Bacteraemia) and clean with SPRI beads prior to sequencing; effectively removing inhibitors common to blood culture media, including sodium polyanetholsulfonate [26]. The results indicate no inhibition of WGS library preparation using this protocol. The method does not require specialist equipment or reagents, so is cost efficient and straightforward to implement in a range of settings.

Avoiding the use of specialist reagents allows the method to be used for most bacteria, exploiting the non-specificity of WGS to allow diagnosis to encompass the 20–25 pathogens causing most BSI, as well as rarer pathogens and known resistance conferring genes/mutations and virulence genes [6]. The use of specific lysis reagents, such as lysostaphin, may improve lysis of some target organisms (for example, Staphylococcus sp.) while kits such as the MolYsis Basic5 kit (Molzym, Germany) may reduce human DNA further. The effect of our and other potential methods on DNA concentrations for different bacterial species, including intracellular pathogens, should be explored in future investigations.

The complexity of WGS laboratory protocols and bioinformatics analysis is often viewed as an impediment to implementation in clinical settings [29, 30]. However, kit-based sequencing preparation methods (such as Nextera XT), paired with the Illumina MiSeq and bioinformatics tools designed for clinical usage (such as Mykrobe Predictor) have already enabled the roll-out of WGS-based infectious disease diagnosis for organisms such as Mycobacterium tuberculosis [31]. For Gram-negative bacteria a WGS-resistance prediction tool designed for clinical usage has not yet been made widely available, leading to the use of Kraken and an in-house tool (resist\(\text{T}\)ype) in this study. However, as an area of rapid development, we anticipate that a suitable tool will be available in the near-future [32–34].

Using our method, species identification and drug susceptibility prediction could be performed with >93 % concordance to clinical diagnostic results. We note discordance with low sequencing quality, co-infections, and high human DNA content, which reduce the number of reads available for susceptibility prediction and increases the likelihood of low-confidence predictions. For unknown reasons, the number of Gram-negative BSI identified as co-infections

### Table 4. MinION read statistics as generated by nanoStats.py (https://github.com/nick297/fast5_scripts; commit vb88e14a)

| Sample | Organism | Total bases | No. of reads | Average read length (bp) | Longest read (bp) | Median read length (bp) |
|--------|----------|-------------|--------------|--------------------------|------------------|------------------------|
| 1      | E. coli  | 11 664 010  | 4762         | 2449                     | 11 296           | 2009                   |
| 2      | E. coli  | 108 669 599 | 48 592       | 2236                     | 22 752           | 1881                   |
| 3      | S. aureus| 473 680 151 | 221 196      | 2142                     | 25 178           | 1690                   |
| 4      | S. aureus| 303 247 664 | 116 769      | 2597                     | 27 285           | 2086                   |
| 5      | E. coli  | 9 902 327   | 4 138        | 2393                     | 17 368           | 2020                   |
| 6      | Fail     | 58 924      | 29           | 2032                     | 6 979            | 1483                   |
| 7      | Fail     | 12 539      | 6            | 2090                     | 3 286            | 1810                   |
| 8      | Fail     | 29 926      | 21           | 1425                     | 4 149            | 1027                   |
| 9      | S. aureus| 29 940 810  | 12 035       | 2488                     | 23 878           | 1884                   |
was high during this study at 27 % (12/44) versus reported rates of 6–12 % [19]. For 3/12 of these, phenotypic investigations identify the co-infecting organism in the unsequenced bottle. Information regarding the distribution of species in individual culture bottles is unavailable for the remainder. Performing WGS with both aerobic/anaerobic blood culture bottles, or a mixture of the two, would avoid missing additional pathogens in the future. Although WGS may identify co-infections present in the same culture bottle more readily than MALDI-TOF MS [4], further investigations are required to confirm this potential and determine limits of detection.

WGS reports three very major errors (phenotype resistant, genotype sensitive) for co-amoxiclav resistance in Gram-negative bacteria. However, 15 % discordance between co-amoxiclav MICs generated by automated microbroth dilution and gradient diffusion has previously been observed [25]; while repetition of automated microbroth dilution generates differing susceptibility predictions in 5 % of samples [25]. There remains a clear requirement for further investigations to explore the genotype-phenotype relationship for co-amoxiclav.

The timeliness of appropriate antimicrobial therapy is crucial to the reduction of BSI-related morbidity and mortality. To this end, an 8 h turnaround from positive blood culture to full diagnosis is targeted; although the World Health Organisation and Centres for Disease Control aim for a 2 h turnaround time [5]. WGS with Illumina MiSeq currently takes 23–59 h (in this study approximately: 3 h DNA extraction; 4 h sequencing library preparation; 16–52 h MiSeq-based sequencing; Mykrobe data processing <2 min per sample). At 23 h potential turnaround time, WGS is equivalent to current culture-based methods (~24 h) and potentially offers more information. However, for MiSeq-based WGS sample batching would be required to reduce overall costs, increasing turnaround times according to local BSI specimen throughput.

An alternative approach is to explore sequencing directly from blood or plasma [35]. Sequencing circulating cell-free DNA from plasma permits species and limited antimicrobial-resistance diagnosis based on <1× coverage depth [35]. Although by-passing culture steps provides rapid turnaround, this method does not yet provide robust data for full resistance prediction.

MinION-based WGS with computational support can also reduce turnaround times; predicting species within 4 h of culture positivity (in this study: 3 h DNA extraction; 1 h for sequencing library preparation and species identification) and subsequently generating drug-resistance predictions [36]. The MinION is random access (reducing the requirement for sample batching) and permits real-time sequencing data analysis; minimizing these time-delays. This turnaround time begins to rival MALDI-TOF, even with rapid subculture [7, 10], and microarray approaches where <4 h turnaround times are reported [37]; with the advantage of being un-restricted by a target panel and capable of
generating resistance predictions. Given the rapid development of MinION-based sequencing, a <4 h time from positive blood culture to species identification of any organism, drug susceptibility prediction and phylogenetic placement is becoming increasingly tangible. Application to direct from blood/plasma sequencing would similarly reduce diagnostic time [35], and provide a crucial step towards point-of-care BSI diagnosis. However, in this investigation 3/9 MinION sequencing runs failed to generate sufficient data for analysis; suggesting optimization of methods to improve robustness is required. MinION sequencing may also prove to be prohibitively expensive, with uncertain potential surrounding the ability to multiplex samples and thus reduce costs.

We demonstrate that DNA of sufficient quantity and quality can be extracted from positive blood culture bottles to allow species identification and drug-resistance prediction using MiSeq- and MinION-based WGS. WGS offers the potential for an end-to-end diagnostic solution, replacing the multiple clinical workflows currently used to support species identification and drug susceptibility testing. Further investigations are required to assess the performance of WGS in parallel with routine clinical testing.

**Funding information**

This study was supported by the Health Innovation Challenge Fund [a parallel funding partnership between Wellcome Trust (WT098615/Z/12/2) and the Department of Health (grant T5–3581) and the NIHR Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at University of Oxford in partnership with Public Health England (PHE) (grant HPRU-2012-10041)]. In addition this research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and University of Oxford. Zamin Iqbal was funded by a Wellcome Trust/Royal Society Sir Henry Dale Fellowship (grant 102541/Z/13/Z) and Phelimi Bradley was funded by a Wellcome Trust PhD studentship. The views expressed in this publication are those of the authors and not necessarily those of the NHS, NIHR, PHE, Wellcome Trust or the Department of Health. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

**Acknowledgements**

The authors would like to thank Phuong Quan (NDM, University of Oxford) and the clinical laboratory staff for their assistance. Modernizing Medical Microbiology Informatics Group (MMMIG): Tanya Golubchik, Vasiliki Kostiou, Carlos del Ojo Elias, Dilrini de Silva, Anna Shepherd, Milind V Acharya, Laura Madrid Marquez, Pete Welch, Oriol Mazariegos Canellas, Jeremy Swann, Trien Do.

**Conflicts of interest**

The authors declare that there are no conflicts of interest.

**Ethical statement**

Because this was a method development study and did not return results for clinical management, research ethics committee approval was not required in the UK.

**References**

1. Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect 2013;19:501–509.

2. Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 2016;193:259–272.

3. Bhattacharyya A, Nsonwu O, Johnson A, Hope R. Thirty-day all-cause mortality subsequent to MRSA, MSSA and E. coli bacteremia and C. difficile infection, 2016/17. Public Health England. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/637436/HCAI_thirty_day_allcause_mortality_report_2016_2017.pdf; 2017.

4. Afshari A, Schrenzel J, Ieven M, Harbarth S. Bench-to-bedside review: rapid molecular diagnostics for bloodstream infection—a new frontier? Crit Care 2012;16:222.

5. Buehler SS, Madison B, Snyder SR, Derzon JH, Cornish NE et al. Effectiveness of practices to increase timeliness of providing targeted therapy for inpatients with bloodstream infections: a laboratory medicine best practices systematic review and meta-analysis. Clin Microbiol Rev 2016;29:59–103.

6. Fan SL, Miller NS, Lee J, Remick DG. Diagnosing sepsis — the role of laboratory medicine. Clin Chim Acta 2016;460:203–210.

7. Loonen AJ, Wolfs PF, Bruggeman CA, van den Brule AJ. Developments for improved diagnosis of bacterial bloodstream infection. Eur J Clin Microbiol Infect Dis 2014;33:1687–1702.

8. Opta O, Croxatto A, Prod’hom G, Greub G. Blood culture-based diagnosis of bacteremia: state of the art. Clin Microbiol Infect 2015;21:313–322.

9. Vardakas KZ, Anifantaki F, Trigkidis KK, Falagas ME. Rapid molecular diagnostic tests in patients with bacteremia: evaluation of their impact on decision making and clinical outcomes. Eur J Clin Microbiol Infect Dis 2015;34:2149–2160.

10. Williamson DA, Heffernan H, Nimmo G. Contemporary genomic approaches in the diagnosis and typing of Staphylococcus aureus. Pathology 2015;47:270–275.

11. Antimicrobial Resistance Strategy Analytical Working Group. Antimicrobial Resistance Empirical and Statistical Evidence-Base. UK: Department of Health; 2016.

12. Köck R, Wüllenweber J, Horn D, Lanckohr C, Becker K et al. Implementation of short incubation MALDI-TOF MS identification from positive blood cultures in routine diagnostics and effects on empiric antimicrobial therapy. Antimicrob Resist Infect Control 2017;6:12.

13. Dubourg G, Raoult D. Emerging methodologies for pathogen identification in positive blood culture testing. Expert Rev Mol Diagn 2016;16:97–111.

14. Morgenthaler NG, Kostrzewa M. Rapid identification of pathogens in positive blood culture of patients with sepsis: review and meta-analysis of the performance of the sepsityper kit. Int J Microbiol 2015:2015:1–10.

15. Caspar Y, Garnaud C, Rayкова M, Bailly S, Bidart M et al. Superiority of SDS lysis over saponin lysis for direct bacterial identification from positive blood culture bottle by MALDI-TOF MS. Proteomics Clin Appl 2017;11:1600131.

16. Zborowsycka Y, de La Calle C, Soto M, Sampietro-Colom L, Soriano A et al. Rapid Diagnosis of Staphylococcal Catheter-Related Bacteremia in Direct Blood Samples by Real-Time PCR. PLoS One 2016;11:e0161848.

17. Wang HY, Kim S, Kim J, Park SD, Uh Y et al. Multiplex real-time PCR assay for rapid detection of methicillin-resistant staphylococci directly from positive blood cultures. J Clin Microbiol 2014;52:1911–1920.

18. Jukes L, Mikhail J, Bome-Mannathoko N, Hadfield SJ, Harris LG et al. Rapid differentiation of Staphylococcus aureus, Staphylococcus epidermidis and other coagulase-negative staphylococci and meticillin susceptibility testing directly from growth-positive blood cultures by multiplex real-time PCR. J Med Microbiol 2010;59:1456–1461.

19. Ledebor NR, Lopansri BK, Dhiman N, Cavagnolo R, Carroll KC et al. Identification of Gram-negative bacteria and genetic resistance determinants from positive blood culture broths by use of the virgene gram-negative blood culture multiplex microarray-based molecular assay. J Clin Microbiol 2015;53:2440–2472.
20. van den Brand M, Peters RP, Catsburg A, Rubenjan A, Broeke FJ et al. Development of a multiplex real-time PCR assay for the rapid diagnosis of neonatal late onset sepsis. *J Microbiol Methods* 2014;106:8–15.

21. Strauß L, Ruffing U, Abdulla S, Alabi A, Akulenko R et al. Detecting *Staphylococcus aureus* virulence and resistance genes: a comparison of whole-genome sequencing and DNA microarray technology. *J Clin Microbiol* 2016;54:1008–1016.

22. Chang FY, Peacock JE, Musher DM, Triplett P, Macdonald BB et al. *Staphylococcus aureus* bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. *Medicine* 2003;82:333–339.

23. Lebovitz EE, Burbelo PD. Commercial multiplex technologies for the microbiological diagnosis of sepsis. *Mol Diagn Ther* 2013;17:221–231.

24. Gordon NC, Price JR, Cole K, Everitt R, Morgan M et al. Prediction of *Staphylococcus aureus* antimicrobial resistance by whole-genome sequencing. *J Clin Microbiol* 2014;52:1182–1191.

25. Stoesser N, Batty EM, Eyre DW, Morgan M, Wyllie DH et al. Predicting antimicrobial susceptibilities for *Escherichia coli* and *Klebsiella pneumoniae* isolates using whole genome sequence data. *J Antimicrob Chemother* 2013;68:2234–2244.

26. Regan JF, Furtado MR, Brevnov MG, Jordan JA. A sample extraction method for faster, more sensitive PCR-based detection of pathogens in blood culture. *J Mol Diagn* 2012;14:120–129.

27. Trung NT, Hien TT, Huyen TT, Quyen DT, van Son T et al. Enrichment of bacterial DNA for the diagnosis of blood stream infections. *BMC Infect Dis* 2016;16:235.

28. Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. *Genome Biol* 2014;15:R46.

29. Bradley P, Gordon NC, Walker TM, Dunn L, Heys S et al. Rapid antibiotic-resistance predictions from genome sequence data for *Staphylococcus aureus* and *Mycobacterium tuberculosis*. *Nat Commun* 2015;6:10063.

30. Fricke WF, Rasko DA. Bacterial genome sequencing in the clinic: bioinformatic challenges and solutions. *Nat Rev Genet* 2014;15:49–55.

31. Public Health England. 2017. England world leaders in the use of whole genome sequencing to diagnose TB. www.gov.uk/government/news/england-world-leaders-in-the-use-of-whole-genome-sequencing-to-diagnose-tb [accessed 24th August 2017].

32. Hunt M, Mather AE, Sánchez-Busó L, Page AJ, Parkhill J et al. ARIBA: rapid antimicrobial resistance genotyping directly from sequencing reads. *Microb Genom* 2017;3:e000131.

33. Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ et al. SRST2: Rapid genomic surveillance for public health and hospital microbiology labs. *Genome Med* 2014;6:90.

34. GoSeqIt. 2017. GoSeqIt sequence-based microbial diagnostics. www.goseqit.com/ [accessed 29th August 2017].

35. Grumaz S, Stevens P, Grumaz C, Decker SO, Weigand MA et al. Next-generation sequencing diagnostics of bacteremia in septic patients. *Genome Med* 2016;8:73.

36. Votintseva AA, Bradley P, Pankhurst L, del Ojo Elias C, Loose M et al. Same-day diagnostic and surveillance data for tuberculosis via whole-genome sequencing of direct respiratory samples. *J Clin Microbiol* 2017;55:1285–1298.

37. Felsenstein S, Bender JM, Sposto R, Gentry M, Takemoto C et al. Impact of a rapid blood culture assay for Gram-positive identification and detection of resistance markers in a pediatric hospital. *Arch Pathol Lab Med* 2016;140:267–275.

---

**Five reasons to publish your next article with a Microbiology Society journal**

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review — average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at microbiologyresearch.org.